Abbott Reports Two Hepatitis C Relapses in ‘Pilot’ Trial

Few relapses were reported among patients taking Abbott Laboratories’ experimental hepatitis C treatment, according to a study.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.